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One of the major pathological landmarks of Alzheimer’s disease and other neurodegenerative diseases is
the presence of amyloid deposits in the brain. The early non-invasive visualization of amyloid is a major
objective of recent diagnostic neuroimaging approaches, including positron emission tomography (PET),
with an eye on follow-up of disease progression and/or therapy efficacy. The development of molecular
imaging biomarkers with binding affinity to amyloid in the brain is therefore in the forefront of imaging
biomarker and radiochemistry research. Recently, a dodecamer peptide (amino acid sequence = QSHYR-
HISPAQV; denominated D1 or ACI-80) was identified as a prospective ligand candidate, binding with high
ex vivo affinity to L-Ab-amyloid (Kd: 0.4 lM). In order to assess the ligand’s capacity to visualize amyloid
in Alzheimer’s disease (AD), two 125I labeled and three 18F labeled analogues of the peptide were synthe-
sized and tested in post mortem human autoradiography experiments using whole hemisphere brain
slices obtained from deceased AD patients and age matched control subjects. The 18F-labeled radioligands
showed more promising visualization capacity of amyloid that the 125I-labeled radioligands. In the case of
each 18F radioligands the grey matter uptake in the AD brains was significantly higher than that in control
brains. Furthermore, the grey matter: white matter uptake ratio was over 2, the difference being signif-
icant for each 18F-radioligands. The regional distribution of the uptake of the various radioligands system-
atically shows a congruent pattern between the high uptake regions and spots in the autoradiographic
images and the disease specific signals obtained in adjacent or identical brain slices labeled with histo-
logical, immunohistochemical or autoradiographic stains for amyloid deposits or activated astrocytes.
The present data, using post mortem human brain autoradiography in whole hemisphere human brains
obtained from deceased AD patients and age matched control subjects, support the visualization capacity
of the radiolabeled ACI-80 analogues of amyloid deposits in the human brain. Further studies are war-
ranted to explore the usefulness of the 18F-labeled analogues as in vivo molecular imaging biomarkers
in diagnostic PET studies.
 2011 Elsevier Ltd. All rights reserved.ll rights reserved.
disease; ARG, Autoradiogra-
ry acidic protein; G/W ratio,
ine oxidase-B enzyme; OD,1. Introduction
Alzheimer’s disease (AD) is a debilitating neurodegenerative
disorder for which no therapies are available that can halt or de-
lay the disease process. A number of potential drugs, however, are
under investigation in early clinical phases and it therefore
Table 1
List of investigated D-enantiomeric peptide compounds. Modifications in the original
amino acid sequence of ACI-80 are printed in bold. Other modifications of the amino
acid sequence are printed in italics. FITC: fluorescein isothiocyanate.
Name of compound Amino acid sequence Modification
[125I]-ACI-80 QSHYRHISPAQV-(125I) D1-[125I]
[125I]-ACI-80-F QSHYRHISPAQV-(125I)-
FITC
D1-FITC
[18F]-ACI-87-F QSHYRHISPAQK-(18F)-FITC D1-V12K-[19F]-FITC
[18F]-ACI-88-F SHYRHISPAQK-(18F)-FITC Q1X-D1-V12 K-[19F]-
FITC
[18F]-ACI-89-F PSHYRHISPAQK-(18F)-FITC D1-Q1P-V12 K-[19F]-FITC
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disease are developed in parallel. AD has especially great impor-
tance for the society as with increased life expectancy world-wide
the proportion of AD patients is increasing. For example the
number of AD patients between 2006 and 2050 is expected to
quadruple (Brookmeyer et al., 2007, 2011). This causes heavy
challenges to the health care and social system in particular since
approximately 40% of the prevalent cases need intense level of
care. Despite intensive research efforts in the past decades, the
reliable diagnosis of AD is still based on the post mortem demon-
stration of amyloid plaques and neurofibrillary tangles in the dis-
eased person’s brain. A reliable early in vivo clinical diagnostic
approach would be a unique asset, but is still seriously hampered
by the lack of diagnostic probes with sufficient sensitivity and
specificity.
With the help of molecular imaging techniques, including pos-
itron emission tomography (PET), molecular alterations, underly-
ing pathological conditions leading to brain diseases, can be
recognized distinctively in its early phase. Consequently, they have
a unique potential to identify very early molecular dysfunctions
that are predictive for the imminent or future development of
AD, they are useful for early diagnosis, prognosis prediction, re-
fined diagnostic classification, and quantification and follow-up
of drug treatment efficacy. In line with this potential of molecular
imaging techniques, especially PET, the search for molecular imag-
ing biomarkers as diagnostic probes for PET investigations in the
early phase of AD has been intensified during the past years (Rabi-
novici and Jagust, 2009; Cavedo and Frisoni, 2011; Prvulovic and
Hampel, 2011; Scheinin et al., 2011; Galimberti and Scarpini,
2011).
Amyloid and insoluble Ab peptides have been identified as dis-
ease biomarkers (Andreasen and Zetterberg, 2008; Hampel et al.,
2008; Svedberg et al., 2009; Lin et al., 2010a,b) for which molecular
imaging biomarkers have also been developed (Klunk et al., 2004;
Nordberg, 2007, 2008; Cai et al., 2007). Activated microglia and the
up-regulated peripheral benzodiazepine (PBR) or, as it is recently
called, 18 kDa translocator protein (TSPO) system (Banati, 2002;
Venneti et al., 2006; Chen and Guilarte, 2008; Gavish et al., 1999;
Gulyás et al., 2002a,b, 2009, 2011a,b) are other evident candidates,
as are, among others, b-adrenergic receptors (Wang et al., 2011; Yu
et al., 2011), activated astrocytes and the MAO-B system (Schwab
and McGeer, 2008; Fuller et al., 2009; Rodríguez et al., 2009; Razi-
far et al., 2006; Johansson et al., 2007; Gulyás et al., 2011a,b,c; Nag
et al., 2011). For the latter targets, molecular imaging biomarkers
are already available (Fowler et al., 1995; Kumlien et al., 1995;
Reutens, 2000; Kassiou et al., 2005; Dollé et al., 2009; Gulyás
et al., 2011a,b,c). Other targets, including cardinal neurotransmit-
ter receptors and transporters, neuromodulatory and neuroregula-
tory proteins, have also been considered.
During the search for an appropriate molecular imaging bio-
marker for amyloid, a dodekamer peptide (amino acid
sequence = QSHYRHISPAQV; denominated D1 or ACI-80) was iden-
tified as a prospective ligand binding with high ex vivo affinity to
L-Ab-amyloid (Kd: 0.4 lM) (Schumacher et al., 1996; Wiesehan
et al., 2003; Wiesehan andWillbold, 2003). More recently, the mol-
ecule’s potential for reducing plaque load in transgenic (tg) mice by
one of its analogues (van Groen et al., 2008, 2009) and the inhibi-
tion of cell toxicity and neurofibrillary tangle formation by ACI-80
were also demonstrated (Wiesehan et al., 2008), indicating the
compound’s therapeutic property, in addition to its diagnostic
potential.
In order to demonstrate the affinity of ACI-80 to amyloid pla-
ques in the human brain in AD and with an eye on using the com-
pound in in vivo imaging studies as a molecular imaging biomarker
for AD, we have performed ex vivo experiments using [18F]-radiola-
beled and [125I]-labeled analogues of the compound.The studies included whole hemisphere autoradiographic
experiment on brain slices obtained from both AD patients and
age matched controls. In order to demonstrate the presence of
amyloid plaques in the AD brain tissue and the congruence be-
tween the autoradiographic signal and the presence of amyloid
plaques, immunohistochemical studies were performed in the
same brains.2. Methods
2.1. Radiochemistry
2.1.1. Synthesis of [125I]-compounds ([125I]ACI-80 and [125I]ACI-80-F)
The peptides to be labeled (D1 or ACI-80 and ACI-80-F) were re-
ceived from the Forschungszentrum Jülich, Germany. Chloramide-
T was obtained from Aldrich, potassium iodide and PBS (pH 7.0)
from Fluka, Iodide-125 (10 mCi/100 ll) from PerkinElmer. Peptide
monoiodides were analysed and purified by HPLC (Merck Hitachi),
equipped with UV detector and radiodetector (Packard). A semi-
preparative reverse phase column (Waters l-Bondapak C18,
10 m, 8.7  300 mm) was used with a UV detector set at 22 nm.
The reaction mixture comprised 10 ll Na 125I (1 mCi), 100 ll pep-
tide, 1 mg/ml EtOH in water (1/1, v/v), 300 ll BPS (pH 7.0), 100 ll
chloramine-T (3 mg/2 ml water). The reaction mixture stood at
room temperature for 1–2 min and then was loaded into the HPLC
column, eluted with mobile phase trifluoroacetic acid (0.1%, v/v):
MeOH (72/28, v/v) at flow rate 3 ml/min. The solvent from the col-
lected fraction was removed by evaporator below 40 C under vac-
uum afforded the respective peptide iodide, which was then
formulated with 50% ethanol in water. The analysis of the peptide
monoiodides was performed in the same HPLC system and its iden-
tification was made by an LC–MS system (Waters Q-Tof Premier
mass spectrometer system with Acquity UPLC). Radiochemical
purity was more than 98%. The investigated D-enantiomeric pep-
tide compounds are listed in Table 1 and the radiolabeled peptides’
structures are shown in Fig. 1.2.1.2. Synthesis of [18F]-compounds ([18F]ACI-87-F, [18F]ACI-88-F,
[18F]ACI-89-F)
The variants of ACI-80, labeled with [18F], were designed for
increased stability in water and increased binding strength com-
pared to ACI-80 (cfr. Table 1). N-succinimidyl-4-[18F]fluorobenzo-
ate ([18F]SFB) was synthesized based on the literature method with
modifications (Tang et al., 2008; Johnström et al., 2008). To a solu-
tion of [18F]-SFB (200 ll – 900 MBq) in acetonitrile, peptide
(1.2 mg) in borate buffer (150 ll, pH = 8.8) was added and kept
at room temperature (RT) for 10 minutes. The reaction mixture
was then injected into C18 lBondapak reverse phase analytical
HPLC column (3.9  300 mm, 10 lm, Waters) using a gradient
method MeCN-0.1% TFA (20% of MeCN to 50% MeCN) as eluent
with flow rate of 2 ml/min. The effluent was monitored with UV
absorbance detector (k = 224 nm) in series with a GM tube
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Fig. 1. Structure of the [125I]-labeled ACI-80 compounds: [125I]ACI-80 and [125I]ACI-80-F.
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lected (Rt = 10–12 min) in a pre-filled slightly basic (pH was ad-
justed with NaOH) aqueous solution (40 ml). This diluted product
fraction was then passed through a C18 Sep-Pak plus cartridge
(preconditioned with 10 ml EtOH + 10 ml water) and the desired
product, ([18F]ACI-87-F, [18F]ACI-88-F, [18F]ACI-89-F), was eluted
with 1 ml of ethanol. The identity of these radiotracers ([18F]-pep-
tides) were confirmed using HPLC by co-injecting with an unla-
beled reference of [19F]-peptides. The radiotracers were
formulated in phosphate buffered saline (PBS; pH = 7.4; 7 ml)
and filtered through a sterile filter (0.22 lm; Millipore, Sweden)
into a sterile vial for in vivo applications. Total time of synthesis
was 40 min from the end of synthesis of [18F]-SFB. The radiochem-
ical purity of [18F]-peptides were >98% and the obtained specificradioactivity values were for [18F]ACI-87-F 16 GBq/lmol and
11 GBq/lmol, for [18F]ACI-88-F 113 GBq/lmol and 9 GBq/lmol,
and for [18F]ACI-89-F 86 GBq/lmol and 27 GBq/lmol. The investi-
gated D-enantiomeric peptide compounds are listed in Table 1 and
the radiolabeled peptides’ structures are shown in Fig. 2.
2.1.3. Synthesis of reference peptides
To an aqueous solution of peptide, borate buffer (0.5 M,
pH = 8.61) was added and the color of the solution changed from
yellow to dark orange. Slightly excess amount of SFB in acetonitrile
was added into this above solution and the reaction mixture was
kept at RT for 10 min. The reaction was monitored by HPLC. The
crude product was purified by an analytical HPLC column
(3.9  300 mm, 10 lm, Waters, Milford, MA) using a gradient
156 B. Gulyás et al. / Neurochemistry International 60 (2012) 153–162method MeCN-0.1% TFA (20% of MeCN to 50% MeCN) as eluent
with flow rate of 2 ml/min. Retention times for the three reference
peptides were from 9 to 12 min and the wavelength was
k = 234 nm. The product fraction was then collected into a pre-
filled slightly basic aqueous solution (40 ml, pH was adjusted by
NaOH). This diluted fraction was passed through a C18 Sep-Pak
plus cartridge (preconditioned with 10 ml EtOH + 10 ml water)
and the desired product was eluted with 1 ml of ethanol. The ref-
erence compounds were confirmed by LC–MS/MS. The purity and
the stability of the products were analyzed by HPLC.
2.1.4. Synthesis of [11C]-L-deprenyl
The MAO-B imaging radiotracer [11C]-L-deprenyl was labeled as
described earlier (Gulyás et al., 2011a,b,c).
2.2. Brain tissue
Fresh frozen whole hemisphere brain slices of human brains
were received from the Alzheimer Research Group of the Albert
Szent-Györgyi Medical and Health Science Center, University of
Szeged, Hungary. The samples used for the present and consequent
studies included brains from 4 Alzheimer’s patients and 5 age-
matched control subjects whereof only a selected sample size is re-
ferred to in the present investigation. Ethical permission was ob-
tained from the Research Ethics Committee of the University of
Szeged (1895/2004, Hungary). The post mortem time interval
was between 2.5 h and 5.0 h. The patients’ age was between 50
and 98 years, and the collection of AD brains covered Braak stages
between I/II–V. The brains had been removed during clinical au-
topsy and were handled in a manner similar to that described pre-
viously (Hall et al., 1998; Varnäs et al., 2004; Gulyás et al., 2009,
2010, 2011). The sectioning of the brains and all further autoradio-
graphic procedures were performed at the Department of Clinical
Neuroscience, Karolinska Institutet, Stockholm, Sweden. Coronal
brain slices of 100 lm thickness were made in a Leika cryomacro-
cut system. Ethical permission for the autoradiographic experi-
ments were obtained from the Regional Research Ethics
Committee of North Stockholm, Sweden (2010/372-32).
2.3. Autoradiography
2.3.1. 125I compounds ([125I]ACI-80 and [125I]ACI-80-F)
[125I]ACI-80 and [125I]ACI-80-F ARG was performed on 100 lm
thick coronal slices of whole human hemispheres obtained from
two Alzheimer’s patients: a 50 year old female (Braak stage II–III)
and a 96 year old female (Braak stage V). The incubation buffer
consisted of 50 mM Tris–HCl containing the salts NaCl, KCl, CaCl2,
MgCl2, as well as 0.01% ascorbic acid and 0.01% bovine serum albu-
mine, pH 7.4. Further to preliminary experiments on human brain
slices with a series of increasing radioligand concentrations, an
optimal concentration was determined and in the present experi-
ments the incubation solution contained the radioligand in
4.0 nM concentration. The rinsing buffer contained 50 mM Tris-
HCl (no salt) with pH 7.4. The incubation was done for 60 min at
room temperature (RT). Rinsing was then performed twice for
5 min at 4 C with rinsing buffer (see above) at RT; followed by dip-
ping in ice cold distilled water. The slides were then placed on an
imaging plate (Fujifilm Plate BAS-TR2025, Fujifilm, Tokyo, Japan)
for 22–24 h. The plates were developed and the resulting images
were processed in a Fujifilm BAS-5000 phosphorimager (Fujifilm,
Tokyo, Japan). Aliquots (20 ll) of the incubation solution were
spotted onto polyethylene-backed absorbent paper (Bench-
Guard™), allowed to dry, scanned and digitized in the phosphorim-
ager parallel with the tissue scans. The ARG signal’s optical density
(OD) was measured, using Multi Gauge 3.2 image analysis software
(Fujifilm, Tokyo, Japan). Using the known radioactivity value of thealiquots and the OD values, we could also quantify the radioligand
uptake values in various brain structures in nM/g units.
2.3.2. 18F compounds (ACI-87-F, ACI-88-F, ACI-89-F)
Using [18F]-labeled ACI-87-F, ACI-88-F, ACI-89-F ARG was per-
formed on fresh frozen whole hemisphere brain slices of human
brains obtained from both AD patients and aged matched control
subject.
The ARG was performed on fresh frozen whole hemisphere
brain slices. The measurements were done in duplicates. Incuba-
tion of [18F]ACI-87-F, [18F]ACI-88-F and [18F]ACI-89-F was prepared
at radioligand concentration of 0.02 MBq/ml for 90 min, at room
temperature (RT). The incubation buffer consisted of 50 mM Tris-
HCl containing the salts NaCl, KCl, CaCl2, MgCl2, as well as 10 lM
pargylin and 0.3% bovine serum albumine, pH 7.4. The rinsing buf-
fer contained 50 mM TRIS HCl (no salt), the pH was 7.4. Rinsing
was then performed three times for 5 min at 4 C with rinsing buf-
fer; followed by dipping in ice cold distilled water.
The exposed brain slices were placed on an image plate (Fuji-
film Plate BAS-TR2025, Fujifilm, Tokyo, Japan) for at least
120 min. The readings were made and digitized in a Fujifilm BAS-
5000 phosphorimager (Fujifilm, Tokyo, Japan).
Aliquots (20 ll) of the incubation solution (0.02 MBq/ml) and
the diluted incubation solution (50% incubation solution: 50% TRIS
buffer; 0.01 MBq/ml) were spotted onto polyethylene-backed
absorbent paper (BenchGuard), allowed to dry, scanned and digi-
tized in the phosphorimager parallel with the tissue scans.
The ARG signal was quantified using Multi Gauge 3.2 image
analysis software (Fujifilm, Tokyo, Japan). The average ratios (five
measurements per structure per brain) of grey matter-white mat-
ter uptake, expressed in radioactivity uptake (Bq/g; the gram-value
represents ‘‘dry’’ tissue weight throughout the paper) of the three
[18F]-D-peptides ([18F]ACI-87-F, [18F]ACI-88-F and [18F]ACI-89-F)
in the Alzheimer’s disease and age matched control brain slices
were calculated. Using the known radioactivity value of the ali-
quots and the OD values, we could also quantify the radioligand’s
radioactivity uptake values in various brain structures in Bq/g
units.
2.3.3. [11C]deprenyl autoradiography
In order to have a ‘‘reference measurement’’, by using
[11C]deprenyl as an established radioligand labeling activated
astrocytes in neuroinflammation, ARG was performed on fresh fro-
zen whole hemisphere brain slices of human brains from both AD
patients and aged matched control subject as reference for the
localization of activated astrocytes in the brain slices. The proce-
dures were identical with those described by Gulyás et al. (2011).
2.4. Histology and immunohistochemistry: human brain
2.4.1. Amyloid staining with Congo red
Fresh frozen brain slices of 100 lm thickness were fixed in
0.1 M TBS (Tris-buffered saline; pH 7.5) containing 4% formalde-
hyde for 10 min and washed for 3  5 min in 0.1 M TBS in RT. Tis-
sue autofluorescence was inhibited by staining the sections with
Mayer hematoxylin solution (100 mg hematoxylin, 20 mg Na-io-
date, 5 g aluminum potassium sulfate, 5 g trichloroacet-aldehyde
nitrate and 100 mg citric acid dissolved in 100 ml) for 2 min,
washed for 5 min in tap water, and rinsed for a few seconds in dis-
tilled water (all in RT). The sections were then incubated in an eth-
anolic saturated NaCl solution (50 ml of a saturated NaCl solution
(30 g NaCl, 200 ml distilled water, 800 ml 100% ethanol) and
0.5 ml 1% NaOH) for 30 min at 60 C. The sections were then trans-
ferred to a Congo red solution (1:1 solution A:solution B; solution
A: 1 g Congo red, 1 g sodium carbonate, 100 ml distilled water;
solution B: 50 ml distilled water, 50 ml 100% ethanol) and
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tilled water and covered in a mixture (1:1) of glycerine/distilled
water and coverslipped.2.4.2. Astrocyte staining with GFAP immunohistochemistry (DAB)
The cryostat sections were fixed in 0.5 M PBS (phosphate-buf-
fered saline; pH 7.5) containing 4% formaldehyde for 10 min and
washed for 3  5 min in 0.05 M PBS in room temperature (RT).
After blocking the endogenous peroxidases in 1% H2O2 for 30 min
in 37 C, the sections were washed for 3  5 min in 0.05 M PBS.
The tissue sections were permeabilized and the background bind-
ing of the antibodies were reduced in a blocking solution (0.05 M
PBS solution containing 3% NGS, 1% BSA, 0.05% Triton X-100) for
60 min at 37 C. Sections were then covered with a solution con-
taining mouse anti GFAP primary antibody (diluted to 1:500 in
the blocking solution) at 4 C overnight, then washed for
4  10 min in 0.05 M PBS in RT. The sections were treated with a
biotinylated anti mouse IgG secondary antibody diluted (1:200)
in the blocking solution (where Triton X-100 was omitted) for
6 h at RT. After several washes (4  10 min), biotinylated streptavi-
din-peroxidase tertiary antibody (1:200) in the blocking solution
(without Triton X-100) overnight at 4 C.
The sections were washed again in 0.05 M PBS for 4  10 min at
RT and processed for peroxidase enzyme histochemistry. The sec-
tions were pre-incubated in a filtered 0.05 M PBS solution contain-
ing 0.5 mg/ml DAB for 20 min at RT, and then developed in the
same solution but also containing 0.01% H2O2 for 10–20 min at
RT. The sections were finally washed for 3  5 min in 0.05 M PBS,
mounted on glass slides, dehydrated in a series of alcohol solu-
tions, covered with DPX and coverslipped.Fig. 3. Autoradiography, histochemistry and immunohistochemistry results obtained in
50 year old female AD patient, Braak II–III; D–F: Brains slices obtained from a 96 year old
and E: autoradiograms obtained with [125I]-ACI-80-F. C: Congo red stain demonstrating a
amyloid deposits. F: GFAP immunohistochemistry, displaying activated astrocyes. In the z
black (A, B, D and E): 20 mm, scale bars in white (C and F): 50 lm.3. Results
3.1. [125I]-labeled compounds
Autoradiographic images, together with characteristic immuno-
histochemical images, from the two AD brains are displayed in
Fig. 3. At visual inspection and at microscopic investigation, both
brains showed clear signs of degeneration and atrophy compatible
with the disease. Artifacts due to the acquisition and conservation
of the tissue were also seen. Congo red stain, performed on adja-
cent sections showed intense diffuse staining throughout the sec-
tions in both patients’ brain, together with abundant Congo red
positive plaques. GFAP staining of the brains indicated extensive
and clear-cut astrocyte activation in the tissue.
[125I]-ACI-80 ARG of both brains displayed very distinct cortical
and sub-cortical labels in form of distinct spots and a diffuse label
of the cortical areas including the hippocampus. The ARG signal in
brain of the older patient with higher Braak-grade (Braak stage V)
was clearly stronger than that in the brain of the younger patient
with lower Braak-grade (Braak II–III), compatible with an increased
plaque load in the former. For [125I]ACI-80-F a similar, though more
diffuse labeling pattern was seen in both brains as compared to the
pattern obtained with [125I]ACI-80. The average (± standard error
of means, SEM) uptake of [125I]-ACI-80 in the cortical grey matter
was 0.478 ± 0.020 nM/g, and for the white matter it was 0.396 ±
0.017 nM/g, and for the hippocampus it was 0.457 ± 0.020 nM/g
(n.s.). The grey matter:white matter ratio was 1.21 (p = 0.0002),
the hippocampus:white matter ratio was 1.15 (p = 0.0369). The
average uptake of [125I]-ACI-80-F in the cortical grey matter was
0.435 ± 0.016 nM/g, for the white matter it was 0.407 ± 0.019whole hemisphere sections of two AD brains. A–C: Brains slices obtained from a
female AD patient, Braak V. A and D: autoradiograms obtained with [125I]-ACI-80. B
myloid deposition in the brain. In the zoomed-up panel red-orange plaques indicate
oomed-up panel the cells stained in dark-grey are activated astrocytes. Scale bars in
Fig. 4. [18F] ACI-87F, [18F] ACI-88F and [18F] ACI-89F autoradiography in an Alzheimer’s and a control brain. Autoradiographs of human brain hemispheres demonstrating
total [18F]ACI-87-F, [18F]ACI-88-F and, [18F]ACI-89-F binding in coronal sections at the level of hippocampus. The brain slices were obtained form a 50 year old female with AD
(A–C) and an age matched control subject (50 years female, D–F).
Table 2
Radioligand uptake values for the three ligands ([18F] ACI-87-F, [18F] ACI-88-F and
[18F] ACI-89-F) in an Alzheimer’s and a control brain and their ratios. The levels of
significance of the differences are shown in Table 3 (Student’s t-test, one tailed,
158 B. Gulyás et al. / Neurochemistry International 60 (2012) 153–162nM/g, and for the hippocampus it was 0.425 ± 0.019 nM/g. The
grey matter:white matter ratio was 1.07 (n.s.), the hippocam-
pus:white matter ratio was 1.04 (n.s.).unequal variance). Values are expressed in radioactivity uptake in the brain tissue
(average ± SEM; Bq/g. Values were obtained from five ROI’s (region-of-interest) in
each slice. G: grey matter, W: white matter.
[18F]ACI-87-F [18F]ACI-88-F [18F]ACI-89-F
Control G 4.15 ± 0.10 4.95 ± 0.18 5.08 ± 0.14
W 2.72 ± 0.06 3.53 ± 0.08 4.00 ± 0.08
G/W ratio 1.53 1.40 1.27
AD G 4.98 ± 0.26 6.46 ± 0.35 7.57 ± 0.27
W 2.28 ± 0.10 3.12 ± 0.16 4.23 ± 0.27
G/W ratio 2.18 2.07 1.79
AD: control G:G 1.20 1.31 1.49
W:W 0.84 0.88 1.063.2. [18F]-labeled compounds
ARG with [18F]ACI-87-F, [18F]ACI-88-F, and [18F]ACI-89-F was
performed in coronal brain slices of a 50 year old female with AD
(Braak II–III – same brain as used for [125I] ARG shown in Fig. 2)
and on coronal slices of an aged matched control patient (54 years,
female).
As can be seen in Fig. 4, [18F]ACI-87F, [18F]ACI-88F and [18F]ACI-
89F ARG showed a diffuse signal in the cortical layers and ventral
and dorsal hippocampal formation in the AD patients. The radioli-
gand uptake values in the cortical grey matter, the white matter
and in the hippocampus, as well as the grey matter:white matter
and hippocampus:white matter ratios for the three radioligands
in the diseased and control brains are shown in Table 2, the corre-
sponding significance values are displayed in Table 3. The signal
was distinctively stronger in AD brains that in the brains obtained
from age matched control subjects. Also, while in the control sub-
jects’ brain the layers of the hippocampal formation are visible, the
ARG signal in the hippocampus of the AD patient was diffuse, more
intense and there were no layers visible. Moreover, some verystrong labeled spots in the cortical areas and hippocampus of the
Alzheimer’s patient were visible for all there radioligands:
[18F]ACI-87-F, [18F]ACI-88-F and [18F]ACI-89-F. This was practically
absent in the slices of the control brain.
As shown in the table and in the images, the signal in the cortex
and hippocampus was more intense in the case of AD brains as
compared to the age matched control brains.
Table 3
Levels of significant differences between parametric values shown in Tables
(Student’s t-test, one tailed, unequal variance). G: grey matter, W: white matter,
Ctrl: control, vs: versus.
[18F]ACI-87-F [18F]ACI-88-F [18F]ACI-89-F
G vs W Ctrl *** *** ***
AD *** *** ***
Ctrl vs AD G *** *** ***
W ** * n.s.
[18F]ACI-87-F vs.
[18F]ACI-88-F
[18F]ACI-87-F vs.
[18F]ACI-89-F
[18F]ACI-88-F vs.
[18F]ACI-89-F
G vs G Ctrl ** *** n.s.
AD ** *** *
W vs W Ctrl *** *** ***
AD ** *** n.s.
n.s., not significant.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
Fig. 6. Histochemical staining with Congo red (panels A and B) and autoradiogra-
phy (panels C–F) obtained from adjacent brain slices (100 lm thickness) from the
same AD patient (50 years old female, Braak stage II–III). Magnifications in panels A
and C–F are identical and the scale bar indicates 1 cm. The scale bars in B is 100 lm.
The radioligands were [125I]ACI-80 (C), [18F]ACI-87-F (D), [18F]ACI-88-F (E) and
[18F]ACI-89-F (F).
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labeled compounds and with [11C]-L-deprenyl
In addition to labeling amyloid deposits in the brain, compli-
mentary ARG was performed using [11C]-L-deprenyl, an established
molecular imaging biomarker of activated astrocytes and the MAO-
B system, in order to visualize astrocyte activation and the upreg-
ulation of MAO-B, as a sign of neuroinflammation, concurrent with
amyloid deposits in AD. As shown in Fig. 5, the spotty up-take pat-
tern, observed in the cortex of the brain of AD patients with the
radioflurinated ACI peptides, was also seen with [11C]-L-deprenyl,
although due to the different energy ranges of 11C and 18F the
up-take pattern was more blurred. This may indicate a concurrent
neuroinflammation, resulting in the up-regulation of astrocytes, in
the very same regions where the higher regional up-take of the
radioflurinated ACI peptides indicates amyloid depositions.
3.4. Comparison of autoradiography and histochemichal and
immunohistochemical data
In order to visualize the pattern of regional amyloid depositions
in the brain and compare this with the ARG findings, we performed
histochemical amyloid staining with Congo red in brain slices,Fig. 5. [11C]-L-deprenyl, [18F]ACI-87-F, [18F]ACI-88-F and [18F]ACI-89-F autoradiography.
patient. B–E: [11C]deprenyl, [18F]ACI-87-F, [18F]ACI-88-F and [18F]ACI-89-F autoradiograp
square in A, and, consequently, the size of panels B–E, are 13  13 mm.adjacent to those whereon ARG was made. As shown in Fig. 6A, a
diffuse labeling of the tissue was seen with Congo red. High mag-
nification Fig. 6B of the cortical area shows numerous plaques as
indicated by Congo red spots in the photomicrographs. The Congo
red spots are of different size and intensity, indicating both diffuse
and more circumscribed amyloid deposition pattern in the brain of
AD patients. Panels C–F display ARG images of the same sulcus
which is present in panel A. The ARG staining in Fig. 6C was made
with [125I]ACI-80, whereas in Fig. 6D and F they were made with
three radiofluorinated compounds. Despite the fact that the ARG
signals show varying intensities depending upon the radionuclide
([18F] or [125I]) and the compound (ACI-80, ACI-87-F, ACI-88-F,
ACI-89-F), in overall, the immunohistochemical signals are congru-
ent with the ARG signals, indicating increased amyloid deposition
in the cortex of AD brains.
4. Discussion
The advent of molecular imaging techniques, with special re-
gard to PET, has revolutionized diagnostic medicine as the use ofA: [11C]deprenyl autoradiography of whole hemisphere of 50 years old Alzheimer’s
hy at higher magnification of sulcus precentralis of the same patient. The size of the
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provides us with a non-invasive approach to visualize disease spe-
cific biochemical alterations in the human body. In the case of Alz-
heimer’s disease the identification of specific biochemical targets
in the brain, characteristic for the disease, is a key issue in order
to use them as targets for molecular imaging biomarkers and,
eventually, as targets for clinical diagnostic tools.
Most of the biochemical targets which are recently in the fore-
front of molecular imaging biomarker research in AD are partly re-
lated to neuroinflammation-specific intracellular proteins, such as
TSPO in microglia and MAO-B in astrocytes, and partly to patholog-
ical protein deposits, such as defective tau proteins or Ab amyloids.
The pioneering PET radioligand for amyloid imaging is [11C]PIB
(Klunk et al., 2004; Lopresti et al., 2005; Price et al., 2005; Mintun
et al., 2006), which has in been tested widely in the past years in
AD and in other neurodegenerative diseases, including Lewy body
disease (LBD) (Maetzler et al., 2009), mild cognitive impairment
(MCI) (Forsberg et al., 2008; Koivunen et al., 2011), fronto-tempo-
ral dementia (FTD) (Engler et al., 2008), Parkinson’s disease
(Johansson et al., 2008) and amyotrophic lateral sclerosis (ALS)
(Yamakawa et al., in press). Based on the accumulated evidence,
a careful evaluation of the imaging capacity of [11C]PIB suggests
that imaging biomarkers with shorter brain wash-out time and
with lower non-specific binding in the brain, with special regard
to the white matter, would be more advantegous in diagnostic
amyloid imaging in the future. In order to identify more suitable
amyloid PET radioligands, the search for, and testing of, novel com-
pounds has intensified during recent years. Radiolabeled com-
pounds with binding affinity for amyloid has been developed and
tested, including [18F]AV-45 (Choi et al., 2009; Lin et al., 2010a,b;
Liu et al., 2010; Yao et al., 2010), [11C]AZD2184 (Anderson et al.,
2010; Johnson et al., 2009; Nyberg et al., 2009), [18F]AZD4694
(Juréus et al., 2010), [18F]BAY94-9172 (Rowe et al., 2008; O’Keefe
et al., 2009).
Recently the dodekapeptide D1 (QSHYRHISPAQV) has been
identified as a prospective ligand with high ex vivo binding affin-
ity to beta-amyloid (Schumacher et al., 1996; Wiesehan et al.,
2003; Wiesehan and Willbold, 2003), and with in vivo staining
characteristics in transgenic AD mouse models (van Groen et al.,
2008, 2009). The peptide has been radiolabeled with F18 and its
radiolabeled analogues were successfully tested in post mortem
human brain tissue for amyloid staining (Jahan et al., in press).
The present study aimed at a detailed autoradiographic investiga-
tion of various D1 analogues, radiolabeled with 125I or 18F, in
whole hemisphere human brain slices obtained from AD patients
and age matched control subjects. Disease specific signs in the AD
brain tissue were confirmed with immunohistochemistry as well
as with complimentary autoradiographic studies using [11C]-L-
deprenyl, a radioligand of activated astrocytes and up-regulated
MAO-B.
The histological studies, using the amyloid stain Congo red,
demonstrated the presence of amyloid in the whole hemisphere
human brain slices identical with, or adjacent to, the slices used
for the ARG measurements. The immunohistochemical studies
using the astrocyte stain DAB confirmed in the same regions the
presence of activated astrocytes which are present in and around
amyloid deposits (Mrak and Griffin, 2001; Mrak, 2009). This obser-
vation was further supported by ARG studies in brain slices, adja-
cent to the slices used for autoradiography with the radiolabeled
peptides, stained with the MAO-B radioligand [11C]-L-deprenyl.
The ARG studies using both the 125I and 18F labeled peptide ana-
logues visualized high regional radioligand uptake in those regions
which were identified with the aforementioned histological,
immunohistochemical and autoradiographic techniques, indicat-
ing the radioligands’ s binding to amyloid in post mortem human
brain tissue.Regarding the comparison between the 125I-labeled and
18F-labeled peptides, in the AD brains the latter ones yielded better
contrast between grey matter and white matter (range: 1.07–1.21
vs. 1.79–2.18, 125I and 18F, respectively). In the case of the 125I-la-
beled radioligands, [125I]-ACI-80 had a better grey matter: white
matter contrast and the uptake differences between the two brain
compartments were significant, whereas [125I]-ACI-80-F yielded
lower contrast between the grey matter and white matter and
the uptake differences were not significant. In the case of the
18F-labeled radioligands [18F]ACI-89-F had the highest uptake val-
ues in both grey matter and white matter 7.57 vs. 4.23 Bq/g,
respectively), but at the same time the contrast between grey mat-
ter and white matter uptakes was the lowest one among the three
18F-labeled compounds (1.79). On the other hand, [18F]ACI-87-F
yielded the lowest uptake values in grey and white matter (4.98
vs. 2.28 Bq/g, respectively), but the highest contrast (2.18). Finally,
[18F]ACI-88-F had the medium uptake values and contrast (values:
6.46 vs. 3.12 Bq/g; contrast: 2.07). Regarding the 18F-labeled radio-
ligands, this was the rank order not only in the case of the AD
brains but also in the case of age matched control brains, wherein
for each radioligands the uptake values for the grey matter compo-
nents were lower than the corresponding values in AD brains. The
grey matter: white matter contrast in all cases were significant.
Using [3H]PIB, the grey matter: white matter binding ratios, i.e.
contrast, in AD brains were around 1, whereas they were between
4 and 6 with [3H]AZD2184, the radioligand know for its most its
lowest white matter uptake until today (Johnson et al., 2009).
Taken together all this evidence, the present investigations sup-
port the potential of the radiolabeled analogues of ACI-80, with
special regard to [18F]ACI-89-F, as potential molecular imaging bio-
markers for amyloid in the human brain. Further in vivo neuroim-
aging studies are required to explore the 18F-labeled radioligands’
imaging capacity as prospective molecular imaging biomarkers of
amyloid deposits in the living human brain.
Disclosure
During the process of this study, AC Immune entered into re-
search agreement with Karolinska Institutet based on the technol-
ogy described in this article. Dieter Willbold is a co-inventor of D1
and a consultant for AC Immune. All authors listed as having an AC
Immune affiliation are AC Immune employees. Christian Spenger is
an employee of Prodema Medical which coordinated the experi-
ments between the different parties involved.
Acknowledgements
This work was supported by grants of AC Immune. The authors
express their gratitude to Siv Eriksson for the technical perfor-
mance of the autoradiographic experiments and to Paolo Paganetti
for help in preparing the manuscript.
References
Andreasen, N., Zetterberg, H., 2008. Amyloid-related biomarkers for Alzheimer’s
disease. Curr. Med. Chem. 15, 766–771.
Andersson, J.D., Varnäs, K., Cselényi, Z., Gulyás, B., Wensbo, D., Finnema, S.J., Swahn,
B.M., Svensson, S., Nyberg, S., Farde, L., Halldin, C., 2010. Radiosynthesis of the
candidate beta-amyloid radioligand [(11)C]AZD2184: positron emission
tomography examination and metabolite analysis in cynomolgus monkeys.
Synapse 64, 733–741.
Banati, R.B., 2002. Visualising microglial activation in vivo. Glia 40, 206–217.
Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, H.M., 2007. Forecasting the
global burden of Alzheimer’s disease. Alzheimers Dement. 3, 186–191.
Brookmeyer, R., Evans, D.A., Hebert, L., Langa, K.M., Heeringa, S.G., Plassman, B.L.,
Kukull, W.A., 2011. National estimates of the prevalence of Alzheimer’s disease
in the United States. Alzheimers Dement. 7, 61–73.
Cai, L., Innis, R.B., Pike, V.W., 2007. Radioligand development for PET imaging of
beta-amyloid (Abeta) – current status. Curr. Med. Chem. 14, 19–52.
B. Gulyás et al. / Neurochemistry International 60 (2012) 153–162 161Cavedo, E., Frisoni, G.B., 2011. The dynamic marker hypothesis of Alzheimer’s
disease and its implications for clinical imaging. Q. J. Nucl. Med. Mol. Imag. 55,
237–249.
Chen, M.K., Guilarte, T.R., 2008. Translocator protein 18 kDa (TSPO) molecular
sensor of brain injury and repair. Pharmacol. Ther. 118, 1–17.
Choi, S.R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Hefti, F., Benedum, T.E.,
Kilbourn, M.R., Skovronsky, D., Kung, H.F., 2009. Preclinical properties of 18F-
AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 50, 1887–1894.
Dollé, F., Luus, C., Reynolds, A., Kassiou, M., 2009. Radiolabeled molecules for
imaging the translocator protein (18 kDa) using positron emission tomography.
Curr. Med. Chem. 16, 2899–2923.
Engler, H., Santillo, A.F., Wang, S.X., Lindau, M., Savitcheva, I., Nordberg, A., Lannfelt,
L., Långström, B., Kilander, L., 2008. In vivo amyloid imaging with PET in
frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imag. 35, 100–106.
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim,
A., Långström, B., Nordberg, A., 2008. PET imaging of amyloid deposition in
patients with mild cognitive impairment. Neurobiol. Aging. 29, 1456–1465.
Fowler, J.S., Wang, G.J., Logan, J., Xie, S., Volkow, N.D., MacGregor, R.R., Schlyer, D.J.,
Pappas, N., Alexoff, D.L., Patlak, C., Wolf, A.P., 1995. Selective reduction of
radiotracer trapping by deuterium substitution: comparison of carbon-11-L-
deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J. Nucl. Med. 36,
1255–1262.
Fuller, S., Münch, G., Steele, M., 2009. Activated astrocytes: a therapeutic target in
Alzheimer’s disease? Expert Rev. Neurother. 9, 1585–1594.
Galimberti, D., Scarpini, E., 2011. Progress in Alzheimer’s disease. J Neurol. (Epub
ahead of print).
Gavish, M., Bachman, I., Shoukrun, R., Katz, Y., Veenman, L., Weisinger, G., Weizman,
A., 1999. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev. 51,
629–650.
Gulyás, B., Sóvágó, J., Sandell, J., Halldin, C., Cselényi, Z.M., Vas, Á., Kiss, B., Kárpáti, E.,
Farde, L., 2002. Drug distribution in man: a positron emission tomography
study after oral administration of the labeled neuroprotective drug vinpocetine.
Eur. J. Nucl. Med. 29, 1031–1038.
Gulyás, B., Halldin, C., Sandell, J., Swahn, C.-G., Bönöck, P., Kiss, B., Vas, Á., Cselényi,
Z.M., Vas, Á., Farde, L., 2002. PET studies on the uptake and regional
distribution of [11C]vinpocetine in human subjects. Acta Neurol. Scand. 106,
325–332.
Gulyás, B., Makkai, B., Kása, P., Gulya, K., Bakota, L., Várszegi, S., Beliczai, Z.,
Andersson, J., Csiba, L., Thiele, A., Dyrks, T., Suhara, T., Suzuki, K., Higuchi, M.,
Halldin, C., 2009. A comparative autoradiography study in post mortem whole
hemisphere human brain slices taken from Alzheimer patients and age-
matched controls using two radiolabeled DAA1106 analogues with high
affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem.
Int. 54, 28–36.
Gulyás, B., Brockschnieder, D., Nag, S., Pavlova, E., Kása, P., Beliczai, Z., Légrádi, A.,
Gulya, K., Thiele, A., Dyrks, T., Halldin, C., 2010. The norepinephrine transporter
(NET) radioligand (S, S)-[18F]FMeNER-D2 shows significant decreases in NET
density in the human brain in Alzheimer’s disease: a post-mortem
autoradiographic study. Neurochem. Int. 56, 789–798.
Gulyás, B., Pavlova, E., Kása, P., Gulya, K., Bakota, L., Várszegi, S., Keller, E., Horváth,
M.C., Nag, S., Hermecz, I., Magyar, K., Halldin, C., 2011a. Activated MAO-B in the
brain of Alzheimer patients, demonstrated by [(11)C]-l-deprenyl using whole
hemisphere autoradiography. Neurochem. Int. 58, 60–68.
Gulyás, B., Vas, A., Tóth, M., Takano, A., Varrone, A., Cselényi, Z., Schain, M., Mattsson,
P., Halldin, C., 2011b. Age and disease related changes in the translocator
protein (TSPO) system in the human brain: positron emission tomography
measurements with [(11)C]vinpocetine. Neuroimage 56, 1111–1121.
Gulyás, B., Tóth, M., Vas, A., Shchukin, E., Kostulas, K., Hillert, J., Halldin, C., 2011.
Visualising neuroinflammation in post-stroke patients: a comparative PET
study with the TSPO molecular imaging biomarkers [(11)C]PK11195 and
[(11)C]Vinpocetine. Curr. Radiopharm. (Epub ahead of print).
Hall, H., Halldin, C., Farde, L., Sedvall, G., 1998. Whole hemisphere autoradiography
of the postmortem human brain. Nucl. Med. Biol. 25, 715–719.
Hampel, H., Bürger, K., Teipel, S.J., Bokde, A.L., Zetterberg, H., Blennow, K., 2008. Core
candidate neurochemical and imaging biomarkers of Alzheimer’s disease.
Alzheimers Dement. 4, 38–48.
Jahan, M., Nag, S., Krasikova, R., Weber, U., Muhs, A., Spenger, C., Willbold, D.,
Gulyás, B., Halldin, C., in press. Flourine-18 labeling of three novel D-Peptides by
conjugation with N-succinimidyl-4-[F-18]fluorobenzoate and preliminary
examination by post mortem whole hemisphere human brain
autoradiography. Nul. Med. Biol.
Johansson, A., Engler, H., Blomquist, G., Scott, B., Wall, A., Aquilonius, S.M.,
Långström, B., Askmark, H., 2007. Evidence for astrocytosis in ALS
demonstrated by [11C](L)-deprenyl-D2 PET. Neurol. Sci. 255, 17–22.
Johansson, A., Savitcheva, I., Forsberg, A., Engler, H., Långström, B., Nordberg, A.,
Askmark, H., 2008. [(11)C]-PIB imaging in patients with Parkinson’s disease:
preliminary results. Parkinsonism Relat Disord. 14, 345–347.
Johnson, A.E., Jeppsson, F., Sandell, J., Wensbo, D., Neelissen, J.A., Juréus, A., Ström, P.,
Norman, H., Farde, L., Svensson, S.P., 2009. AZD2184: a radioligand for sensitive
detection of beta-amyloid deposits. J. Neurochem. 108, 1177–1786.
Johnström, P., Clark, J.C., Pickard, J.D., Davenport, A.P., 2008. Automated synthesis of
the generic peptide labeling agent N-succinimidyl 4-[18F]fluorobenzoate and
application to 18F-label the vasoactive transmitter urotensin-II as a ligand for
positron emission tomography. Nucl. Med. Biol. 35, 725–731.
Juréus, A., Swahn, B.M., Sandell, J., Jeppsson, F., Johnson, A.E., Johnström, P.,
Neelissen, J.A., Sunnemark, D., Farde, L., Svensson, S.P., 2010. Characterization ofAZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J.
Neurochem. 114, 784–794.
Kassiou, M., Meikle, S.R., Banati, R.B., 2005. Ligands for peripheral benzodiazepine
binding sites in glial cells. Brain Res. Brain Res. Rev. 48, 207–210.
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergström,
M., Savitcheva, I., Huang, G.F., Estrada, S., Ausén, B., Debnath, M.L., Barletta, J.,
Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A.,
Långström, B., 2004. Imaging brain amyloid in Alzheimer’s disease with
Pittsburgh Compound-B. Ann. Neurol. 55, 306–319.
Koivunen, J., Scheinin, N., Virta, J.R., Aalto, S., Vahlberg, T., Någren, K., Helin, S.,
Parkkola, R., Viitanen, M., Rinne, J.O., 2011. Amyloid PET imaging in patients with
mild cognitive impairment: a 2-year follow-up study. Neurology 76, 1085–1090.
Kumlien, E., Bergström, M., Lilja, A., Andersson, J., Szekeres, V., Westerberg, C.E.,
Westerberg, G., Antoni, G., Långström, B., 1995. Positron emission tomography
with [11C]deuterium-deprenyl in temporal lobe epilepsy. Epilepsia 36, 712–
721.
Lin, C.J., Huang, H.C., Jiang, Z.F., 2010a. Cu(II) interaction with amyloid-beta peptide:
a review of neuroactive mechanisms in AD brains. Brain Res. Bull. 82, 235–242.
Lin, K.J., Hsu, W.C., Hsiao, I.T., Wey, S.P., Jin, L.W., Skovronsky, D., Wai, Y.Y., Chang,
H.P., Lo, C.W., Yao, C.H., Yen, T.C., Kung, M.P., 2010b. Whole-body
biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid
imaging agent – a pilot study. Nucl. Med. Biol. 37, 497–508.
Liu, Y., Zhu, L., Plössl, K., Choi, S.R., Qiao, H., Sun, X., Li, S., Zha, Z., Kung, H.F., 2010.
Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging
agent for Alzheimer’s disease. Nucl. Med. Biol. 37, 917–925.
Lopresti, B.J., Klunk, W.E., Mathis, C.A., Hoge, J.A., Ziolko, S.K., Lu, X., Meltzer, C.C.,
Schimmel, K., Tsopelas, N.D., DeKosky, S.T., Price, J.C., 2005. Simplified
quantification of Pittsburgh Compound B amyloid imaging PET studies: a
comparative analysis. J. Nucl. Med. 46, 1959–1972.
Maetzler, W., Liepelt, I., Reimold, M., Reischl, G., Solbach, C., Becker, C., Schulte, C.,
Leyhe, T., Keller, S., Melms, A., Gasser, T., Berg, D., 2009. Cortical PIB binding in
Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol.
Dis. 34, 107–112.
Mintun, M.A., Larossa, G.N., Sheline, Y.I., Dence, C.S., Lee, S.Y., Mach, R.H., Klunk,
W.E., Mathis, C.A., DeKosky, S.T., Morris, J.C., 2006. [11C]PIB in a nondemented
population: potential antecedent marker of Alzheimer disease. Neurology 67,
446–452.
Mrak, R.E., Griffin, W.S., 2001. The role of activated astrocytes and of the
neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease.
Neurobiol. Aging 22, 915–922.
Mrak, R.E., 2009. Neuropathology and the neuroinflammation idea. J. Alzheimers
Dis. 18, 473–481.
Nag, S., Lehmann, L., Heinrich, T., Thiele, A., Kettschau, G., Nakao, R., Gulyás, B.,
Halldin, C., 2011. Synthesis of three novel fluorine-18 labeled analogues of l-
deprenyl for positron emission tomography (PET) studies of monoamine
oxidase B (MAO-B). J. Med. Chem. 54, 7023–7029.
Nordberg, A., 2007. Amyloid imaging in Alzheimer’s disease. Curr. Opin. Neurol. 20,
398–402.
Nordberg, A., 2008. Amyloid imaging in Alzheimer’s disease. Neuropsychologia 46,
1636–1641.
Nyberg, S., Jönhagen, M.E., Cselényi, Z., Halldin, C., Julin, P., Olsson, H., Freund-Levi,
Y., Andersson, J., Varnäs, K., Svensson, S., Farde, L., 2009. Detection of amyloid in
Alzheimer‘s disease with positron emission tomography using [11C]AZD2184.
Eur. J. Nucl. Med. Mol. Imag. 36, 1859–1863.
O’Keefe, G.J., Saunder, T.H., Ng, S., Ackerman, U., Tochon-Danguy, H.J., Chan, J.G.,
Gong, S., Dyrks, T., Lindemann, S., Holl, G., Dinkelborg, L., Villemagne, V., Rowe,
C.C., 2009. Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-
BAY94-9172. J. Nucl. Med. 50, 309–315.
Price, J.C., Klunk, W.E., Lopresti, B.J., Lu, X., Hoge, J.A., Ziolko, S.K., Holt, D.P., Meltzer,
C.C., DeKosky, S.T., Mathis, C.A., 2005. Kinetic modeling of amyloid binding in
humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow
Metab. 25, 1528–1547.
Prvulovic, D., Hampel, H., 2011. Amyloid b (Ab) and phospho-tau (p-tau) as
diagnostic biomarkers in Alzheimer’s disease. Clin. Chem. Lab. Med. 49, 367–
374.
Rabinovici, G.D., Jagust, W.J., 2009. Amyloid imaging in aging and dementia: testing
the amyloid hypothesis in vivo. Behav. Neurol. 21, 117–128.
Razifar, P., Axelsson, J., Schneider, H., Langström, B., Bengtsson, E., Bergström, M.,
2006. A new application of pre-normalized principal component analysis for
improvement of image quality and clinical diagnosis in human brain PET
studies–clinical brain studies using [11C]-GR205171, [11C]-L-deuterium-
deprenyl, [11C]-5-Hydroxy-L-Tryptophan, [11C]-L-DOPA and Pittsburgh
Compound-B. NeuroImage 33, 588–598.
Reutens, D.C., 2000. Imaging monoamine oxidase B receptor mapping. Adv. Neurol.
83, 173–176.
Rodríguez, J.J., Olabarria, M., Chvatal, A., Verkhratsky, A., 2009. Astroglia in dementia
and Alzheimer’s disease. Cell Death Differ. 16, 378–385.
Rowe, C.C., Ackerman, U., Browne, W., Mulligan, R., Pike, K.L., O’Keefe, G., Tochon-
Danguy, H., Chan, G., Berlangieri, S.U., Jones, G., Dickinson-Rowe, K.L., Kung,
H.P., Zhang, W., Kung, M.P., Skovronsky, D., Dyrks, T., Holl, G., Krause, S., Friebe,
M., Lehman, L., Lindemann, S., Dinkelborg, L.M., Masters, C.L., Villemagne, V.L.,
2008. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a
novel PET tracer: proof of mechanism. Lancet. Neurol. 7, 129–135.
Scheinin, N.M., Scheinin, M., Rinne, J.O., 2011. Amyloid imaging as a surrogate
marker in clinical trials in Alzheimer’s disease. Q. J. Nucl. Med. Mol. Imag. 55,
265–279.
162 B. Gulyás et al. / Neurochemistry International 60 (2012) 153–162Schumacher, T.N., Mayr, L.M., Minor, D.L., Milhollen, M.A., Burgess, M.W., Kim, P.S.,
1996. Identification of D-peptide ligands through mirror-image phage display.
Science 271, 1854–1857.
Schwab, C., McGeer, P.L., 2008. Inflammatory aspects of Alzheimer disease and
other neurodegenerative disorders. J. Alzheimers Dis. 13, 359–369.
Svedberg, M.M., Hall, H., Hellström-Lindahl, E., Estrada, S., Guan, Z., Nordberg, A.,
Långström, B., 2009. [(11)C]PIB-amyloid binding and levels of Abeta40 and
Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int.
54, 347–357.
Tang, G., Zeng, W.B., Yu, M.X., Kabalka, G., 2008. Facile synthesis of N-succinimidyl
4-[18F]fluorobenzoate ([18F]SFB) for protein labeling. J. Labeled Compounds
Radiopharm. 51, 68–71.
van Groen, T., Wiesehan, K., Funke, S.A., Kadish, I., Nagel-Steger, L., Willbold, D.,
2008. Reduction of Alzheimer’s disease amyloid plaque load in transgenic mice
by D3, A D-enantiomeric peptide identified by mirror image phage display.
ChemMedChem 3, 1848–1852.
van Groen, T., Kadish, I., Wiesehan, K., Funke, S.A., Willbold, D., 2009. In vitro and
in vivo staining characteristics of small, fluorescent, Abeta42-binding D-
enantiomeric peptides in transgenic AD mouse models. ChemMedChem 4,
276–282.
Varnäs, K., Halldin, C., Hall, H., 2004. Autoradiographic distribution of serotonin
transporters and receptor subtypes in human brain. Hum. Brain Mapp. 22, 246–
260.
Venneti, S., Lopresti, B.J., Wiley, C.A., 2006. The peripheral benzodiazepine receptor
(Translocator protein 18 kDa) in microglia: from pathology to imaging. Prog.
Neurobiol. 80, 308–322.Wang, D., Yuen, E.Y., Zhou, Y., Yan, Z., Xiang, Y.K., 2011. Amyloid beta peptide-(1–
42) induces internalization and degradation of beta2 adrenergic receptors in
prefrontal cortical neurons. J. Biol. Chem. 286, 31852–31863.
Wiesehan, K., Buder, K., Linke, R.P., Patt, S., Stoldt, M., Unger, E., Schmitt, B., Bucci, E.,
Willbold, D., 2003. Selection of D-amino-acid peptides that bind to Alzheimer’s
disease amyloid peptide abeta1–42 by mirror image phage display.
Chembiochem 4, 748–753.
Wiesehan, K., Willbold, D., 2003. Mirror-image phage display: aiming at the mirror.
Chembiochem 4, 811–815.
Wiesehan, K., Stöhr, J., Nagel-Steger, L., van Groen, T., Riesner, D., Willbold, D., 2008.
Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid
peptide that specifically binds to Alzheimer’s disease amyloid peptide. Protein
Eng. Des. Sel. 4, pp. 241–216.
Yamakawa, Y., Shimada, H., Ataka, S., Tamura, A., Masaki, H., Naka, H., Tsutada, T.,
Nakanishi, A., Shiomi, S., Watanabe, Y., Miki, T., in press. Two cases of dementias
with motor neuron disease evaluated by Pittsburgh compound B-positron
emission tomography. Neurol Sci.
Yao, C.H., Lin, K.J., Weng, C.C., Hsiao, I.T., Ting, Y.S., Yen, T.C., Jan, T.R., Skovronsky, D.,
Kung, M.P., Wey, S.P., 2010. GMP-compliant automated synthesis of [(18)F]AV-
45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain. Appl.
Radiat. Isot. 68, 2293–2297.
Yu, J.T., Wang, N.D., Ma, T., Jiang, H., Guan, J., Tan, L., 2011. Roles of b-adrenergic
receptors in Alzheimer’s disease: implications of novel therapeutics. Brain Res.
Bull. 84, 111–117.
